Allogene Therapeutics (ALLO) Change in Acquisitions & Divestments (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Change in Acquisitions & Divestments data on file, last reported at $72.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 27.64% year-over-year to $72.1 million; the trailing twelve-month figure through Mar 2026 stood at $15.6 million (up 137.74% YoY), and the FY2024 full-year result was $5.4 million, down 99.1% from the prior year.
• Change in Acquisitions & Divestments grew to $72.1 million in Q1 2026, from -$110.3 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $455.8 million in Q3 2023 to a low of -$215.1 million in Q3 2024.
• A 5-year average of $79.6 million and a median of $72.1 million in 2026 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments plunged 214.84% in 2022 and soared 1736.6% in 2024, its largest moves.
• Tracing ALLO's Change in Acquisitions & Divestments over 5 years: stood at $359.5 million in 2022, then tumbled by 62.07% to $136.3 million in 2023, then slumped by 257.76% to -$215.1 million in 2024, then jumped by 48.72% to -$110.3 million in 2025, then soared by 165.38% to $72.1 million in 2026.
• Business Quant data shows ALLO's Change in Acquisitions & Divestments at $72.1 million in Q1 2026, -$110.3 million in Q3 2025, and $53.8 million in Q2 2025.